Biogen Idec Ltd: UK Public Sector Contracts Won & Awards
Large organisation·Companies House: Private Limited Company·Maidenhead·Scotland·Main market: Pharmaceutical products
Official UK PPONPTGT-3385-PBMQCompanies House01497267 ↗ · Active
Where they wini
i
53 awards (50 for a named lot, 94%, 3 for a whole procedure with no lot named) · top CPV classes, shares of all 53 awards. An award may cover more than one class.
3360 Pharmaceutical products51 awards · 96% · 48 awards naming a lot + 3 whole-procedure awardsi
i
Largest published awards i | Authority | Awarded | Term | Published value |
|---|---|---|---|---|
| Biologic and Biosimilar Medicines | eTenderwales | — | — | £23,169,600 † |
| Interferon Beta-1a (Avonex®) | The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | — | — | £9,913,176 † |
| Transitional Drugs 3 | NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | — | — | £1,140,311 † |
| Proprietary Drugs | eTenderwales | — | — | £948,600 † |
| Proprietary Drugs | NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | — | — | £665,247 † |
Where their buyers arei
i
ITL1 region of the buyer office · known for 38 of 38 awarded procedures · each procedure counts once
Bidding recordi
i
Procurement Act 2023 award notices name every bidder · 4 notices name this supplier, covering 6 lots since 6 Oct 2025 · observed bids, not an estimate
i
i
i
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS National Generic Pharmaceuticals - Wave 16a | NHS England | not appointed | 125 | 9 Oct 2026 |
| NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026 | NHS England | appointedall 2 lots bid for | 25 | 21 Jul 2026 |
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | NHS England | appointedall 2 lots bid for | 26 | 10 Jul 2026 |
| NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 | NHS England | appointed | 17 | 6 Oct 2025 |
Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.
Who they sell toi
i
Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier
i
NHS & health85%(45 awards)
45 of 53 awards are NHS & health (85%).Type not classified15%(8 awards)
8 of 53 awards are Type not classified (15%).
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 15 | 39.5% | 23 | 6 Jul 2026 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") | 10 | 26.3% | 14 | 30 Oct 2025 |
| Regional Business Services Organisation Procurement and Logistics Service | 3 | 7.9% | 6 | 5 Jan 2026 |
| NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | 3 | 7.9% | 3 | 15 Apr 2025 |
| The NHS Commissioning Board (operating under the name of NHS England) | 3 | 7.9% | 3 | 7 Feb 2022 |
| eTenderwales | 2 | 5.3% | 2 | 17 Jun 2025 |
| Belfast Health and Social Care Trust | 2 | 5.3% | 2 | 18 Apr 2024 |
Share = of the 38 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
i
37 of 53 awards carry an end date, 14 estimated from the duration · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| Etanercept | 19 Jan 2027 estimated | £1,700,000 ceiling |
| Infliximab IV | 19 Jan 2027 estimated | £44,300,000 ceiling |
| Lot 1 - CM/PHS/25/5728/01 | 31 May 2027 | £688,834,174 ceiling |
| Medicinal Products - Direct to Trust | 2 Jun 2027 estimated | £210,000,000 ceiling |
| Medicinal Products - with Pharma Funded Homecare Services | 2 Jun 2027 estimated | £174,000,000 ceiling |
| Glatiramer acetate solution for injection pre-filled syringes, interferon beta-1a, cladribine tablets, ozanimod capsules, and natalizumab | 28 Jun 2027 estimated | £47,968,904 ceiling |
| Lot 2 - CM/PHR/25/5730/02 - Natalizumab for London and South of England | 31 Aug 2027 | £35,312,548 ceiling |
Recent awards
Latest 30 of 53 award records naming this supplier
About this data
- One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
- Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
- Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
- Contract end dates. Published on 23 of 53 awards, estimated from the published duration on 14 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
- Source. Official UK public procurement notices (Find a Tender and Contracts Finder), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses both feeds, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.